Recent advances in the management of children with familial Mediterranean fever

International Journal of Clinical Rheumatology

Volumn 8, Issue 2, 2013, Pages 233-245

  Saglam, Celal ^a   Polat, Adem ^a   Jones, Olcay Y ^b   Demirkaya, Erkan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

autoinflammatory disease; colchicine; familial Mediterranean fever; MEFV gene; pyrin marenostrin

Indexed keywords

COLCHICINE; DILTIAZEM; ERYTHROMYCIN; ESTROGEN; ETANERCEPT; INFLIXIMAB; LIDOCAINE; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; SEROTONIN UPTAKE INHIBITOR; STEROID; THALIDOMIDE;

ABDOMINAL PAIN; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALOPECIA; ALTERNATIVE MEDICINE; AMYLOIDOSIS; ARTHRITIS; ARTICLE; AUTONOMIC DYSFUNCTION; AUTOSOMAL RECESSIVE INHERITANCE; BEHCET DISEASE; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CHROMOSOME 16P; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIARRHEA; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; ERYSIPELAS; ERYTHEMA; ETHNIC GROUP; FAMILIAL MEDITERRANEAN FEVER; FEVER; GENE; GENE LOCATION; GENE MUTATION; GRAPEFRUIT JUICE; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LEUKOPENIA; LIVER FAILURE; MEFV GENE; MOLECULAR DIAGNOSIS; MYALGIA; NAUSEA; PATHOGENESIS; PATIENT CARE; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTRACTED FEBRILE MYALGIA; PURPURA; SEX DIFFERENCE; SKIN EDEMA; SPLENOMEGALY; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; URTICARIA; VASCULITIS; VOMITING;

EID: 84875741418     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.13.8     Document Type: Article

References (112)

1. Ozen F. Familial Mediterranean fever. Rheumatol. Int. 26(6), 489-496 (2006)..
2. Sohar E, Gafni J, Pras M et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am. J. Med. 43(2), 227-253 (1967)..
3. Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum. 63(10), 1447-1453 (2009)..
4. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4), 797-807 (1997)..
5. The French FMF consortium. A candidate gene for familial Mediterranean fever. Nat. Genet. 17(1), 25-31 (1997)..
6. Polat A, Demirkaya E, Basbozkurt G et al. A glance at history and future perspectives of childhood auto-inflammatory disorders. Ann. Pediatr. Rheum. 1(1), 17-30 (2012)..
7. De Sanctis S, Nozzi M, Del Torto M et al. Autoinflammatory syndromes: diagnosis and management. Ital. J. Pediatr. 36, 57 (2010)..
8. Tunca M, Akar S, Onen F et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84, 1-11 (2005)..
9. Touitou I, Kone-Paut I. Auto-inflammatory diseases. Best Pract. Res. Clin. Rheumatol. 22(5), 811-829 (2008)..
10. Wise CA, Gillum JD, Seidman CE et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an auto-inflammatory disorder. Hum. Mol. Genet. 11(8), 961-969 (2002)..
11. Daniels M, Shohat T, Brenner-Ullman A, Sohat M. Familial Mediterranean fever: high gene frequency among the non-Ashkenazi and Ashkenazi Jewish populations in Israel. Am. J. Med. Genet. 55, 311-314 (1995)..
12. Ozen S, Karaaslan Y, Ozdemir O et al. Prevalence of juvenile chronic arthritis and Familial Mediterranean fever in Turkey: a field study. J. Rheumatol. 25(12), 2445-2449 (1998).
13. Yilmaz E, Ozen S, Balci B et al. Mutation frequency of Familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur. J. Hum. Genet. 9(7), 553-555 (2001)..
14. Rogers DB, Shohat M, Petersen GM et al. Familial Mediterranean fever in Armenians: autosomal recessive inheritance with high gene frequency. Am. J. Med. Genet. 34, 168-172 (1989)..
15. La Regina M, Nucera G, Diaco M et al. Familial Mediterranean fever is no longer a rare disease in Italy. Eur. J. Hum. Genet. 11(1), 50-56 (2003)..
16. Giaglis S, Papadopoulos V, Kambas K et al. MEFV alterations and population genetics analysis in a large cohort of Greek patients with familial Mediterranean fever. Clin. Genet. 71(5), 458-467 (2007)..
17. Nakamura A, Yazaki M, Tokuda T et al. A Japanese patient with compound heterozygosity for pyrin variant E148Q/M694I. Intern. Med. 44(3), 261-265 (2005)..
18. Shohat M, Magal N, Shohat T et al. Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur. J. Hum. Genet. 7, 287-292 (1999)..
19. Livneh A, Langevitz P, Shinar Y et al. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 6(1), 1-6 (1999)..
20. Ben-Chetrit E, Urieli-Shoval S, Calko S, Abeliovich D, Matzner Y. Molecular diagnosis of FMF: lessons from a study of 446 unrelated individuals. Clin. Exp. Rheumotol. 20, 25-29 (2002)..
21. Majeed HA, El-Shanti H, Al-Khateeb MS, Rabaiha ZA. Genotype-phenotype correlations in Arab patients with familial Mediterranean fever. Semin. Arthritis Rheum. 31, 371-376 (2002)..
22. Brik R, Shinawi M, Kepten I, Berant M, Gershoni-Baruch R. Familial Mediterranean fever: clinical and genetic characterization in a mixed population of Jewish and Arab patients. Pediatrics 103, e70 (1999)..
23. Cattan D, Dervichian M, Thomas M, Dode C, Touitou I. MEFV mutations and phenotype-genotype correlations in north African Jews and Armenians with familial Mediterranean fever. Isr. Med. Assoc. J. 3, 803-804 (2001)..
24. Gershoni-Baruch R, Shinawi M, Leah K, Badarnah K, Brik R. Familial Mediterranean fever: prevalence, penetrance and genetic drift. Eur. J. Hum. Genet. 9, 634-637 (2001)..
25. Yalcinkaya F, Cakar N, Misirlioglu M et al. Genotype-phenotype correlation in a large group of Turkish patients with familial Mediterranean fever: evidence for mutation-independent amyloidosis. Rheumatology (Oxford) 39, 67-72 (2000)..
26. Akar N, Misirlioglu M, Yalcinkaya F et al. MEFV mutations in Turkish patients suffering from familial Mediterranean fever. Hum. Mutat. 15, 118-119 (2000)..
27. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur. J. Hum. Genet. 9, 473-483 (2001)..
28. Centola M, Wood G, Frucht DM et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95(3), 223-231 (2000)..
29. Yigit S, Karakus N, Tasliyurt T et al. Significance of MEFV gene R202Q polymorphism in Turkish familial Mediterranean fever patients. Gene 506(1), 43-45 (2012)..
30. Mansfield E, Chae JJ, Komarow HD et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 98, 851-859 (2001)..
31. Tidow N, Chen X, Muller C et al. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood 95, 1451-1455 (2000)..
32. Masumato J, Taniguchi S, Ayukawa K et al. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J. Biol. Chem. 274, 33835-33838 (1999)..
33. Chae JJ, Komarow HD, Cheng J et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol. Cell 11, 591-604 (2003)..
34. Chae JJ, Cho YH, Lee GS et al. Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 34(5), 755-768 (2011)..
35. Samuels J, Aksentijevich I, Torosyan Y et al. Familial Mediterranean fever at millenium. Clinical spectrum, ancient mutations and a survey of 100 American referrals to the National Institute of Health. Medicine (Baltimore) 77, 268-297 (1998)..
36. Lidar M, Yaqubov M, Zaks N et al. The prodrome: a prominent yet overlooked pre-Attack manifestation of familial Mediterranean fever. J. Rheumatol. 33, 1089-1092 (2006)..
37. Toubi E, Gershoni-Baruch R, Kuten A. Cisplatin treatment triggers familial Mediterranean fever attacks. Tumori 89, 80-81 (2003)..
38. Demirturk L, Ozel AM, Cekem K et al. Co-existence of Helicobacter pylori infection in patients with familial Mediterranean fever (FMF) and the effect of Helicobacter pylori on the frequency and severity of FMF attacks. Dig. Liver Dis. 37, 153-158 (2005)..
39. Cattan D, Notarnicola C, Molinari N et al. Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. Lancet 355, 378-379 (2000)..
40. Livneh A, Langevitz P, Zemer D et al. The changing face of familial Mediterranean fever. Semin. Arthritis Rheum. 26, 612-627 (1996)..
41. Heller H, Gafni J, Michaeli D et al. The arthritis of familial Mediterranean fever (FMF). Arthritis Rheum. 9, 1-17 (1996)..
42. Majeed HA, Rawashdeh M. The clinical patterns of arthritis in children with familial Mediterranean fever. QJM 90, 37-43 (1997)..
43. Sneh E, Pras M, Micheali D, Shanin N, Gafni J. Protracted arthritis in familial Mediterranean fever. Rheumatol. Rehabil. 16(2), 102-106 (1997)..
44. Salai M, Langevitz P, Blankstein A et al. Total hip replacement in familial Mediterranean fever. Bull. Hosp. J. Dis. 53, 25-28 (1993)..
45. Besbas N, Ozdemir S, Saatci I et al. Sacroileitis in familial Mediterranean fever: an unusual presentation in childhood. Turk. J. Pediatr. 41, 387-390 (1999)..
46. Ekinci Z. Musculoskelatal symptoms in familial Mediterranean fever. Ann. Paediatr. Rheum. 1(3), 156-162 (2012)..
47. Kalkan G, Demirkaya E, Acikel C et al. Evaluation of the current disease severity scores in paediatric FMF: is it necessary to develop a new one? Pediatr. Rheumatol. 51(4), 743-748 (2012)..
48. Piram M, Frenkel J, Ozen S et al. A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Ann. Rheum. Dis. 70, 309-314 (2011)..
49. van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin. Exp. Med. 5, 87-98 (2005)..
50. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 351, 659-664 (1998)..
51. Yalcinkaya F, Akar N, Misirlioglu M. Familial Mediterranean fever-Amyloidosis and the Val726A1a mutation. N. Engl. J. Med. 338, 993-994 (1998)..
52. Cazeneuve C, Ajrapetyan H, Papin S et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am. J. Hum. Genet. 67, 1136-1143 (2000)..
53. Bakkaloglu A, Duzova A, Balci B et al. The effect of SAA1, SAA2 polymorphisms on renal amyloidosis and A-SAA levels in patients with FMF. Clin. Exp. Rheumatol. 20(Suppl. 26), S80 (2002)..
54. Akar N, Hasipek M, Akar E et al. Serum amyloid A1 and tumor necrosis factor-A alleles in Turkish familial Mediterranean fever patients with and without amyloidosis. Amyloid 10(1), 12-16 (2003)..
55. Touitou I, Sarkisian T, Medlej-Hashim M et al. International Study Group for phenotype-genotype correlation in familial Mediterranean fever. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum. 56(5), 1706-1712 (2007)..
56. Pras M. Amyloidosis of familial Mediterranean fever and the MEFV gene. Amyloid 7, 289 (2000)..
57. Blum A, Sohar E. The diagnosis of amyloidosis. Ancillary procedures. Lancet 1, 721-724 (1962)..
58. Sungur C, Sungur A, Ruacan S et al. Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever. Kidney Int. 44, 834-836 (1993)..
59. Tishler M, Pras M, Yaron M. Abdominal fat tissue aspirate in amyloidosis of familial Mediteeranean fever. Clin. Exp. Rheumatol. 6, 395-397(1988)..
60. Said R, Hamzeh Y, Said S, Tarawneh M, al-Khateeb M. Spectrum of renal involvement in familial Mediterranean fever. Kidney Int. 41(2), 414-419 (1992)..
61. Rozenbaum M, Naschştz JE, Yudashkin M et al. Cardiovascular autonomic dysfunction in familial Mediterranean fever. J. Rheumatol. 29, 987-989 (2002)..
62. Savi M, Asinari G, Gaudiano V, Olivetti G, Neri TM. Unusual immunologic findings in familial Mediterranean fever. Arch. Intern. Med. 138, 644-645 (1978)..
63. Zlotnick A, Levo Y, Fishel R et al. Circulating immune complexes in familial Mediterranean fever, systemic lupus erythematosus and HBsAg carriers. Harefuah 99, 55-57 (1979)..
64. Schlesinger M, Kopolovic J, Viskoper RJ, Ron N. A case of familial Mediterranean fever with cutaneous vasculitis and immune complexes nephritis: light, electron, and immuno-fluorescent study of renal biopsy. Am. J. Clin. Pathol. 80, 511-514 (1983)..
65. Ozen S. Vasculopathy, Behcet's disease and familial Mediterranean fever. Curr. Opin. Rheum. 11, 393-398 (1999)..
66. Ozen S, Ben-Chetrit E, Bakkaloglu A et al. Polyarteritis nodosa in patients with familial Mediterranean fever: a concomittant disease or a feature of FMF? Semin. Arthritis Rheum. 30, 281-287 (2001)..
67. Tunca M, Akar S, Sirin A, Onen F, Cobankara V; The Turkish FMF Study Group. The results of a nationwide analysis of the characteristics of Turkish familial Mediterranean fever patients. Clin. Exp. Rheum. 20(Suppl. 26), S70 (2002)..
68. Bakkaloglu A, Ozen S, Topaloglu R, Dusunsel R, Simsek H, on behalf of the Turkish FMF Study Group. Associated diseases in Turkish FMF patients: are patients predisposed to develop vasculitides. Clin. Exp. Rheumatol. 20(Suppl. 26), S90 (2002)..
69. Ozdogan H, Arisoy N, Kasapcopur O et al. Vasculitis in familial Mediterranean fever. J. Rheumatol. 24, 323-327 (1997)..
70. Glikson M, Galun E, Schlesinger M et al. Polyarteritis nodosa and familial Mediterranean fever: a report of 2 cases and review of the literatüre. J. Rheumatol. 16, 536-539 (1989)..
71. Tinaztepe K, Gucer S, Bakkaloglu A, Tinaztepe B. Familial Mediterranean fever and polyarteritis nodosa: experience of five pediatric case. A casual relationship or coincidence? Eur. J. Pediatr. 156, 505-506 (1997)..
72. Tekin M, Yalcinkaya F, Tumer N, Akar N, Misirlioglu M, Cakar N. Clinical, laboratory and molecular characteristics of children with familial Mediterranean fever-Associated vasculitis. Acta Paediatr. 89, 177-182 (2000)..
73. Koçak H, Cakar N, Hekimoglu B, Atakan C, Akkök N, Unal S. The coexistence of familial Mediterranean fever and polyarteritis nodosa. Pediatr. Nephrol. 10, 631-633 (1996)..
74. Schwartz T, Langevitz P, Zemer D, Gazit E, Pras M, Livneh A. Behcet's disease in familial Mediterranean fever: characterization of the association between the two diseases. Semin. Arthritis Rheum. 29, 286-295 (2000)..
75. Ozen S, Bakkaloglu A, Yilmaz E et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J. Rheumatol. 30, 2014-2018 (2003)..
76. Gershoni-Baruch R, Broza Y, Brik R. Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schonlein purpura. J. Pediatr. 143, 658-661 (2003)..
77. Touitou I, Magne X, Molinari N et al. MEFV mutations in Behcet's disease. Hum. Mutat. 16, 271-272 (2000)..
78. Livneh A, Langevitz P, Zemer D et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 40, 1879-1885 (1997)..
79. Pras M. Familial Mediterranean fever: past, present and future. Clin. Exp. Rheum. 20(Suppl. 26), 66 (2002)..
80. Yalcinkaya F, Ozen S, Ozcakar B et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology 48, 395-398 (2009)..
81. Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann. Rheum Dis. 61, 79-81 (2002)..
82. Inal A, Yilmaz M, Kendirli SG, Altintas D, Karakoc GB. The clinical and genetical features of 124 children with familial Mediterranean fever: experience of a single tertiary center. Rheumatol. Int. 29, 1279-1285 (2009)..
83. Duzova A, Ozaltin F, Ozan A et al. Bone mineral density in children with familial Mediterranean fever. Clin. Rheumatol. 23, 230-234 (2004)..
84. Frensdorff A, Sohar E, Heller H. Plasma fibrinogen in familial Mediterranean fever. Ann. Intern. Med. 55, 448-455 (1961)..
85. Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 34, 973-977 (1991)..
86. Ozen S. Familial Mediterranean fever: revisiting an ancient disease. Eur. J. Pediatr. 162, 449-454 (2003)..
87. Goldenfinger SE. Colchicine for familial Mediterranean fever. N. Engl. J. Med. 287, 1302 (1972)..
88. Ozkan E, Okur O, Ekmekci A et al. A new approach to the treatment of periodic fever. Med. Bull. Istanbul Med. Fac. 5, 44-49 (1972).
89. Copemann WSC. A Short History of the Gout and the Rheumatic Diseases. University of California Press, Los Angeles, CA, USA (1964)..
90. Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever: a controlled, double-blind study. Ann. Intern. Med. 81, 792-794 (1974)..
91. El-Shanti HI. Familial Mediterranean fever and renal disease. Saudi J. Kidney Dis. Transpl. 14, 378-385 (2003)..
92. Kallinich T, Haffner D, Niehues T et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 119, 474-483 (2007)..
93. Ozturk MA, Kanbay M, Kasapoǧlu B et al. Therapeutic approach to familial Mediterranean fever. Clin. Exp. Rheumotol. 29, 77-86 (2011)..
94. Padeh S. Periodic fever syndromes. Pediatr. Clin. N. Am. 52, 577-609 (2005)..
95. Oner A, Erdogan O, Demircin G, Bulbul M, Memis L. Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatr. Nephrol. 18, 521-526 (2003)..
96. Wallace SL, Ertel NH. Occupancy approach to colchicine dosage. Lancet 2(7685), 1250-1251 (1970)..
97. Padeh S, Livneh A, Pras E et al. Familial Mediterranean Fever in the first two years of life: a unique phenotype of disease in evolution. J. Pediatr. 156(6), 985-989 (2010)..
98. Yalcinkaya F, Ozcakar ZB, Tanyildiz M, Elhan AH. Familial Mediterranean fever in small children in Turkey. Clin. Exp. Rheumatol. 29(4 Suppl. 67), S87-S90 (2011)..
99. Ozkaya N, Yalçinkaya F. Colchicine treatment in children with familial Mediterranean fever. Clin. Rheumatol. 22(4-5), 314-317 (2003)..
100. Sayarlioglu M, Sayarlioglu H, Ozen S, Erkoc R, Gul A. Colchicine-induced myopathy in a teenager with familial Mediterranean fever. Ann. Pharmacother. 37, 1821-1824 (2003)..
101. Harel L, Mukamel M, Amir J, Straussberg R, Cohen AH, Varsano I. Colchicine-induced myoneuropathy in childhood. Eur. J. Pediatr. 157, 853-855 (1998)..
102. Dixon AJ, Wall GC. Probable colchicine-induced neutropenia not related to intentional overdose. Ann. Pharmacother. 35, 192-195 (2001)..
103. Guven AG, Bahat E, Akman S, Artan R, Erol M. Late diagnosis of severe colchicine intoxication. Pediatrics 109, 971-973 (2002)..
104. Savgan Gurol E, Kasapcopur O, Hatemi S et al. Growth and IGF-1 levels of children with familial Mediterranean fever on colchicine treatment. Clin. Exp. Rheumatol. 19(5 Suppl. 24), 72-75 (2001)..
105. Zung A, Barash G, Zadik Z, Barash J. Familial Mediterranean fever and growth: effect of disease severity and colchicine treatment. J. Pediatr. Endocrinol. Metab. 19, 155-160 (2006)..
106. Rabinovitch O, Zemer D, Kurkia E et al. Colchicine treatment in conception and pregnancy: two hundred and thirty-one pregnancies in patients with FMF. Am. J. Reprod. Immunol. 28, 245-246 (1992)..
107. Touitou I. Should patients with FMF undergo BMT. Blood 101, 1205-1206 (2003)..
108. Touitou I, Ben-Chetrit E, Gershoni-Baruch R et al. Allogenic bone marrow transplantation: not a treatment yet for familial Mediterranean fever. Blood 102, 409 (2003)..
109. Rawashdeh MO, Majeed HA. Familial Mediterranean fever in Arab children: prevalence and gene frequency. Eur. J. Pediatr. 155, 540-544 (1996)..
110. Schwabe AD, Peters RS. Familial Mediterranean fever in Armenians: analysis of 100 cases. Medicine (Baltimore) 53, 453-462 (1974)..
111. Migita K, Uehara R, Nakamura Y et al. Familial Mediterranean fever in Japan. Medicine (Baltimore) 91(6), 337-343 (2012)..
112. Infevers: The Registry of Hereditary Auto-inflammatory Disorders Mutations. http://fmf.igh.cnrs.fr/ISSAID/infeverss